Summary:
Click image to enlargeEmalex Biosciences, Inc. - “A Multicenter, PlaceboControlled, Double-Blind, Randomized, ParallelGroup, Phase 2b Study to Evaluate the Efficacy and Safety of Ecopipam Tablets in Children and Adolescent Subjects with Tourette’s Syndrome”
Qualified Participants Must:
• Subjects must be 6 to 18 years of age at time of screening
• Subjects must weigh 18 kg (39.6 lbs)
• Subjects must exhibit both motor and vocal tics that cause impairment with normal routine
• Subjects may not be taking any medications used to treat motor or vocal tics for at least 14 days prior to Baseline
Qualified Participants May Receive:
May receive compensation for time and travel